9EP Stock Overview A biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. More details
Rewards Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
Enanta Pharmaceuticals, Inc. Competitors Price History & Performance
Summary of share price highs, lows and changes for Enanta Pharmaceuticals Historical stock prices Current Share Price US$4.96 52 Week High US$16.10 52 Week Low US$4.96 Beta 0.56 1 Month Change -40.24% 3 Month Change -47.23% 1 Year Change -53.21% 3 Year Change -91.80% 5 Year Change -90.46% Change since IPO -62.12%
Recent News & Updates
Enanta Pharmaceuticals Announces Positive Topline Results from First-In-Pediatrics Phase 2 Study Evaluating Zelicapavir for the Treatment of Respiratory Syncytial Virus Dec 10
New major risk - Revenue and earnings growth Sep 27
New major risk - Revenue and earnings growth Aug 07
Third quarter 2024 earnings released: US$1.07 loss per share (vs US$1.86 loss in 3Q 2023) Aug 06
Enanta Pharmaceuticals, Inc. to Report Q4, 2024 Results on Nov 25, 2024 Aug 06
Enanta Pharmaceuticals, Inc. to Report Q3, 2024 Results on Aug 05, 2024 May 08 See more updates
Enanta Pharmaceuticals Announces Positive Topline Results from First-In-Pediatrics Phase 2 Study Evaluating Zelicapavir for the Treatment of Respiratory Syncytial Virus Dec 10
New major risk - Revenue and earnings growth Sep 27
New major risk - Revenue and earnings growth Aug 07
Third quarter 2024 earnings released: US$1.07 loss per share (vs US$1.86 loss in 3Q 2023) Aug 06
Enanta Pharmaceuticals, Inc. to Report Q4, 2024 Results on Nov 25, 2024 Aug 06
Enanta Pharmaceuticals, Inc. to Report Q3, 2024 Results on Aug 05, 2024 May 08
Second quarter 2024 earnings released: US$1.47 loss per share (vs US$1.79 loss in 2Q 2023) May 07
Enanta Pharmaceuticals, Inc. to Report Q2, 2024 Results on May 06, 2024 May 01
Enanta Pharmaceuticals, Inc. Appoints Matthew P. Kowalsky as Chief Legal Officer Apr 30
First quarter 2024 earnings released: US$1.58 loss per share (vs US$1.39 loss in 1Q 2023) Feb 08
Enanta Pharmaceuticals, Inc., Annual General Meeting, Mar 06, 2024 Jan 27
Enanta Pharmaceuticals, Inc. Announces Retirement of Nathaniel S. Gardiner as Senior Vice President and General Counsel, Effective on or Before March 31, 2024 Dec 27
Independent Director recently sold €129k worth of stock Dec 16
President recently sold €65k worth of stock Dec 08
Full year 2023 earnings released: US$6.38 loss per share (vs US$5.91 loss in FY 2022) Nov 21
Enanta Pharmaceuticals, Inc. to Report Q1, 2024 Results on Feb 07, 2024 Nov 21
New major risk - Share price stability Oct 13
New minor risk - Profitability Aug 09
Third quarter 2023 earnings released: US$1.86 loss per share (vs US$1.53 loss in 3Q 2022) Aug 09
Enanta Pharmaceuticals, Inc. to Report Q4, 2023 Results on Nov 20, 2023 Aug 08
New major risk - Share price stability Jul 06
Insufficient new directors Jul 01
Enanta Pharmaceuticals, Inc. Announces Positive Data from A Phase 1 Clinical Study of Edp-323, an Oral, L-Protein Inhibitor in Development for the Treatment of Respiratory Syncytial Virus Jun 21
Second quarter 2023 earnings released: US$1.79 loss per share (vs US$1.64 loss in 2Q 2022) May 09
Enanta Pharmaceuticals, Inc. to Report Q3, 2023 Results on Aug 07, 2023 May 09
First quarter 2023 earnings released: US$1.39 loss per share (vs US$1.48 loss in 1Q 2022) Feb 08
Enanta Pharmaceuticals, Inc. to Report Q2, 2023 Results on May 08, 2023 Feb 08
Enanta Pharmaceuticals, Inc., Annual General Meeting, Mar 02, 2023 Jan 22
Full year 2022 earnings released: US$5.91 loss per share (vs US$3.92 loss in FY 2021) Nov 22
Enanta Pharmaceuticals, Inc. to Report Q1, 2023 Results on Feb 07, 2023 Nov 22
Enanta Pharmaceuticals, Inc. Initiates Sprint, a Phase 2 Clinical Trial of EDP-235, its Oral, Direct-Acting Antiviral Protease Inhibitor Specifically Designed for the Treatment of COVID-19 Nov 10
Enanta Pharmaceuticals, Inc. Announces New Preclinical Data Supporting the Potential of EDP-235 for the Treatment of COVID-19 Oct 20
Enanta Pharmaceuticals, Inc. Doses First Subject in a Phase 1 Clinical Study of EDP-323, its Novel, Oral L-Protein Inhibitor in Development for the Treatment Respiratory Syncytial Virus Oct 18
Enanta Pharmaceuticals, Inc. Initiates a Phase 2b Clinical Study of EDP-938 in High-Risk Adults with Respiratory Syncytial Virus Oct 04
Enanta Pharmaceuticals, Inc. to Report Q4, 2022 Results on Nov 21, 2022 Aug 10
Enanta Pharmaceuticals, Inc. Announces Appointment of Scott T. Rottinghaus to the Position of Senior Vice President and Chief Medical Officer Aug 09
Third quarter 2022 earnings released: US$1.53 loss per share (vs US$1.19 loss in 3Q 2021) Aug 09
Enanta Pharmaceuticals, Inc. to Report Q3, 2022 Results on Aug 08, 2022 Aug 02
Enanta Pharmaceuticals, Inc Announces Positive Data from A Phase 1 Clinical Study of EDP-235, Its Oral 3Cl Protease Inhibitor Designed for the Treatment of Covid-19 Jul 30 Enanta Pharmaceuticals, Inc.(NasdaqGS:ENTA) dropped from Russell 2000 Growth-Defensive Index
Enanta Pharmaceuticals Reports Topline Data from the RSVP Study of EDP-938 in Otherwise Healthy Adults with Community-Acquired Respiratory Syncytial Virus (RSV) May 19
Second quarter 2022 earnings released: US$1.64 loss per share (vs US$1.09 loss in 2Q 2021) May 11
Enanta Pharmaceuticals, Inc. to Report Q2, 2022 Results on May 09, 2022 May 03
Enanta Pharmaceuticals, Inc. Receives FDA Fast Track Designation for EDP-235, its Oral 3CL Protease Inhibitor Specifically Designed for the Treatment and Prevention of COVID-19 Mar 30
Enanta Pharmaceuticals, Inc. Doses First Subject in a Phase 1 Clinical Study of EDP-235, its Oral 3CL Protease Inhibitor Specifically Designed for the Treatment and Prevention of COVID-19 Feb 17 Enanta Pharmaceuticals, Inc. announced delayed 10-Q filing Feb 11
First quarter 2022 earnings: EPS in line with analyst expectations despite revenue beat Feb 09
Enanta Pharmaceuticals, Inc. to Report Q1, 2022 Results on Feb 08, 2022 Feb 02
Full year 2021 earnings: EPS in line with expectations, revenues disappoint Nov 24
Director Yujiro Hata has joined 3rd company board Aug 24
Enanta Pharmaceuticals, Inc. Doses First Subject in a Phase 1 Clinical Study of EDP-721, Its Oral Hepatitis B Virus RNA Destabilizer Aug 17
Third quarter 2021 earnings released: US$1.19 loss per share (vs US$0.71 loss in 3Q 2020) Aug 11
Enanta Pharmaceuticals Presents New Data for EDP-721, an Oral Hepatitis B Virus RNA Destabilizer, at the European Association for the Study of the Liver (EASL) International Liver Congress™ Jun 24
Enanta Pharmaceuticals, Inc. Reports Positive Data from Phase 1b Study of EDP-514, a Hepatitis B Virus (HBV) Core Inhibitor, in Viremic Chronic HBV Patients Jun 23
Second quarter 2021 earnings released: US$1.09 loss per share (vs US$0.30 loss in 2Q 2020) May 08
Enanta Pharmaceuticals Reports Positive Data from Part 2 of Its Phase 1B Study of Edp-514 in Chronic Hepatitis B Virus Patients on Treatment with A Nucleoside Reverse Transcriptase Inhibitor May 07
First quarter 2021 earnings released: US$0.41 loss per share (vs US$0.68 profit in 1Q 2020) Feb 10
Revenue beats expectations Feb 10
Enanta Pharmaceuticals, Inc. Provides Study Results Feb 09
Enanta Pharmaceuticals, Inc. Appoints Brendan Luu as Senior Vice President, Business Development Jan 28
New 90-day high: €39.80 Jan 27
Enanta Pharmaceuticals, Inc., Annual General Meeting, Mar 02, 2021 Jan 22
Enanta Pharmaceuticals Announces the Appointment of John P. Devincenzo, M.D. as Vice President of Translational Virology Jan 08
Enanta Pharmaceuticals Announces the Appointment of Tara L. Kieffer, Ph.D. as Senior Vice President, New Product Strategy and Development Dec 10
Enanta Pharmaceuticals, Inc. Announces Resignation of George Golumbeski as Director Dec 06
New 90-day low: €34.80 Nov 28
Revenue misses expectations Nov 25
Full year 2020 earnings released: US$1.81 loss per share Nov 25
Enanta Pharmaceuticals, Inc. to Report Q1, 2021 Results on Feb 08, 2021 Nov 25
New 90-day low: €36.40 Oct 19
New 90-day low: €37.60 Sep 23
Third quarter earnings released Aug 12
Third quarter earnings released Aug 06
Enanta Pharmaceuticals, Inc. to Report Q4, 2020 Results on Nov 23, 2020 Aug 06
New 90-day low - €41.00 Jul 24 Shareholder Returns 9EP DE Biotechs DE Market 7D -11.4% 5.8% 2.0% 1Y -53.2% -6.1% 9.6%
See full shareholder returns
Return vs Market: 9EP underperformed the German Market which returned 9.6% over the past year.
Price Volatility Is 9EP's price volatile compared to industry and market? 9EP volatility 9EP Average Weekly Movement 9.6% Biotechs Industry Average Movement 7.4% Market Average Movement 4.9% 10% most volatile stocks in DE Market 11.7% 10% least volatile stocks in DE Market 2.4%
Stable Share Price: 9EP's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 9EP's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. The company’s product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV. Enanta Pharmaceuticals, Inc. has a collaborative development and license agreement with Abbott Laboratories to develop, manufacture, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir.
Show more Enanta Pharmaceuticals, Inc. Fundamentals Summary How do Enanta Pharmaceuticals's earnings and revenue compare to its market cap? 9EP fundamental statistics Market cap €110.74m Earnings (TTM ) -€112.49m Revenue (TTM ) €65.57m
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) 9EP income statement (TTM ) Revenue US$67.64m Cost of Revenue US$0 Gross Profit US$67.64m Other Expenses US$183.68m Earnings -US$116.04m
Last Reported Earnings
Sep 30, 2024
Earnings per share (EPS) -5.48 Gross Margin 100.00% Net Profit Margin -171.58% Debt/Equity Ratio 132.4%
How did 9EP perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2025/01/08 01:17 End of Day Share Price 2025/01/08 00:00 Earnings 2024/09/30 Annual Earnings 2024/09/30
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Enanta Pharmaceuticals, Inc. is covered by 20 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Brian Skorney Baird Geoffrey Meacham Barclays Patrick Trucchio Berenberg
Show 17 more analysts 
